Hims & Hers Health第四季度销售额增长，但对第一季度业绩预期偏低

Core Viewpoint - Hims & Hers Health has reported an increase in quarterly sales and subscription users, but its first-quarter guidance is below Wall Street expectations, amid ongoing legal challenges and regulatory scrutiny [1][6][7]. Financial Performance - The company reported a quarterly profit of $20.6 million, or $0.08 per share, down from $26 million, or $0.11 per share, in the same period last year. Analysts had expected earnings of $0.04 per share [3][9]. - Revenue grew by 28% year-over-year to $617.8 million, slightly below analyst expectations of $619.2 million [4][9]. - The company has 2.5 million subscription users, a 13% increase year-over-year, with average revenue per user rising by 11% to $83 [4][9]. - First-quarter revenue guidance is projected between $600 million and $625 million, lower than the analyst expectation of $653.1 million. Full-year revenue guidance is set at $2.7 billion to $2.9 billion, compared to the analyst average of $2.74 billion [4][9]. Business Expansion - Hims & Hers is accelerating its business expansion, including the recent launch of hormone therapy and lab testing services, and plans to enter international markets through the $1.15 billion acquisition of digital health company Eucalyptus [2][5][9]. - The CEO emphasized the company's efforts to diversify beyond weight loss treatments, stating that GLP-1 drugs are just one aspect of their global consumer platform [8][9]. - The company aims to grow new business segments such as testosterone treatment, menopause care, and testing services, with expectations of each generating over $100 million in annual revenue soon [8][9].